Blueprint
 
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
 
 
For period ending 07 February 2018
 
GlaxoSmithKline plc
(Name of registrant)
 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 
 
Form 20-F x     Form 40-F
 
--
 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
 
Yes      No x
 
 
 
 
 
GlaxoSmithKline plc (the 'Company')
 
 
Transaction notification
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Sir Philip Hampton
 
b)
 
Position/status
 
Non-Executive Chairman
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 to 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£12.78
 
3,423.318
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Professor Sir Roy Anderson
 
b)
 
Position/status
 
Independent Non-Executive Director
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 to 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£12.78
 
562.402
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Mr Vindi Banga
 
b)
 
Position/status
 
Senior Independent Non-Executive Director
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 to 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£12.78
 
2,249.609
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Dr Vivienne Cox
 
b)
 
Position/status
 
Independent Non-Executive Director
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 to 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£12.78
 
415.689
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Ms Lynn Elsenhans
 
b)
 
Position/status
 
Independent Non-Executive Director
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
 
Nature of the transaction
 
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 to 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$36.20
 
1,649.508
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Dr Laurie Glimcher
 
b)
 
Position/status
 
Independent Non-Executive Director
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
 
Nature of the transaction
 
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$36.20
 
1,518.595
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Dr Jesse Goodman
 
b)
 
Position/status
 
Independent Non-Executive Director
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financia instrument
 
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
 
Nature of the transaction
 
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 to 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$36.20
 
536.745
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Ms Judy Lewent
 
b)
 
Position/status
 
Independent Non-Executive Director
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
 
Nature of the transaction
 
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 to 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$36.20
 
589.110
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Mr Urs Rohner
 
b)
 
Position/status
 
Independent Non-Executive Director
 
c)
 
Initial notification/
amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2017 to 31 December 2017.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£12.78
 
562.403
 
d)
 
Aggregated information
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2018-02-07
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 07, 2018 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc